De definitieve gids voor genbewerking.
Menu
Home Leren Nieuws Vraag de Atlas
Verkennen Technologieën Ziekten Behandelingen Klinische onderzoeken Bedrijven Wetenschappers Genen Onderzoek Instellingen
Verder dan geneeskunde Landbouw Ethiek Investeren Wereldkaart
Leren & Tools Begin hier Woordenlijst A–Z Vergelijk technologieën Tijdlijn Lijsten & Rankings AI-agents ★ Opgeslagen API
Over Over ons Methodologie Databronnen Redactioneel beleid Contact Disclaimers

🧭 Begeleide weergave
Nieuw in de genetica? We leggen elk begrip uit terwijl je bladert, in gewone taal. Dezelfde pagina's, met de hulp ingebouwd.

⚡ Expertvisie
Je kent de biologie al. Alleen de inhoud — helder en compact, zonder extra uitleg. Dit is de standaardweergave.

Interfacetaal
Lichte modus

Disease · Neurological disease

Huntington's Disease

A fatal inherited brain disease caused by a toxic protein — where the genetics are unusually clear and the delivery problem is unusually hard.

Preclinical braindelivery problemHTT
Preclinical research Tested in cells and animals only. Most preclinical programmes never reach people, and animal results often do not carry over.

Eenvoudige uitleg

A repeated stretch of DNA in one gene becomes too long, and the protein it makes gains a new, harmful property that slowly kills brain cells controlling movement, thinking and mood. The genetics could not be clearer: inherit the expansion and you will develop the disease. What is not clear is how to get an editing machine into billions of neurons, spread throughout the brain, behind a barrier evolved specifically to keep things out.

Dieper ingaan

Huntington's disease is caused by CAG repeat expansion in HTT, producing mutant huntingtin with a toxic gain of function; it is autosomal dominant with essentially complete penetrance above about 40 repeats. Because the pathology is gain-of-function, silencing or removing the mutant allele is the therapeutic goal — ideally allele-selectively, since wild-type huntingtin has essential functions. Delivery across the blood-brain barrier to sufficient neurons remains unsolved, and the fact that neurons do not divide means homology-directed repair is unavailable.

Two hard problems, not one

Delivery is the obvious one. The less obvious one is selectivity: everyone with Huntington's has one normal copy of the gene and one expanded copy, and the normal copy does something important. A treatment that silences both may create a new problem while solving the old one, so allele-selective approaches — targeting variants that happen to sit on the expanded copy — are an active area.

Non-editing approaches to lowering huntingtin have had a difficult clinical history, which has made the whole field appropriately cautious about this target.

Two hard problems, not one
A neuron with an aggregate of misfolded protein in its cell body. Illustration generated for The CRISPR Atlas — a visual aid, not a photograph or a literal depiction of molecular structure.

Sources

Connected in the Atlas

Every entry on this site is linked to the others it relates to. These connections are part of the record, not a search result.

Technologies

CRISPR-Cas13

Genes

HTT
Alleen educatieve informatie Deze pagina is een naslagbron, geen medisch advies. Onderzoeks- en regelgevingsstatus veranderen; controleer de datum van de laatste update hierboven en verifieer belangrijke informatie bij de vermelde primaire bronnen.